Patterns of lipid-injectable emulsion use in neonatal intensive care units across the United States: A multi-institution survey.
lipids
neonates
parenteral nutrition
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
05
2022
received:
28
03
2022
accepted:
07
06
2022
pubmed:
12
6
2022
medline:
11
1
2023
entrez:
11
6
2022
Statut:
ppublish
Résumé
Lipid-injectable emulsions (ILEs) are a necessity for neonates dependent on parenteral nutrition (PN). In this manuscript, we describe the patterns of ILE use in neonatal intensive care units (NICUs) in the United States (US). An electronic survey was sent to 488 NICUs across the US between December 2020 and March 2021. Survey fields included availability and utilization of various ILE in neonates. The response rate was 22% (107 out of 488). Soybean oil ILE (SO-ILE) and soybean oil, medium-chain triglycerides, olive oil, fish oil ILE (SO, MCT, OO, FO-ILE) had similar availability (87% vs 86%, respectively), and SO, MCT, OO, FO-ILE was more commonly used (SO-ILE, 71% vs SO, MCT, OO, FO-ILE, 86%). Fish oil-ILE (FO-ILE) was used by 55% of centers. SO-ILE was most frequently used with PN and needs <4 weeks without cholestasis (79%). The most common reason for SO, MCT, OO, FO-ILE use was cholestasis (71%). ILE minimization was used by 28% of SO-ILE and 22% of SO, MCT, OO, FO-ILE users; 95% of these centers restrict SO, MCT, OO, FO-ILE to doses ≤2 g/kg/day. Twenty-two percent of centers started FO-ILE at direct bilirubin of >5 mg/dl. The results of this survey reveal significant variability in ILE usage across the US. Lipid minimization with SO, MCT, OO, FO-ILE and initiation of FO-ILE for cholestasis at higher bilirubin thresholds are prevalent. Such reports are crucial for a better understanding of ILE use in the NICU and in future ILE development.
Sections du résumé
BACKGROUND
Lipid-injectable emulsions (ILEs) are a necessity for neonates dependent on parenteral nutrition (PN). In this manuscript, we describe the patterns of ILE use in neonatal intensive care units (NICUs) in the United States (US).
METHODS
An electronic survey was sent to 488 NICUs across the US between December 2020 and March 2021. Survey fields included availability and utilization of various ILE in neonates.
RESULTS
The response rate was 22% (107 out of 488). Soybean oil ILE (SO-ILE) and soybean oil, medium-chain triglycerides, olive oil, fish oil ILE (SO, MCT, OO, FO-ILE) had similar availability (87% vs 86%, respectively), and SO, MCT, OO, FO-ILE was more commonly used (SO-ILE, 71% vs SO, MCT, OO, FO-ILE, 86%). Fish oil-ILE (FO-ILE) was used by 55% of centers. SO-ILE was most frequently used with PN and needs <4 weeks without cholestasis (79%). The most common reason for SO, MCT, OO, FO-ILE use was cholestasis (71%). ILE minimization was used by 28% of SO-ILE and 22% of SO, MCT, OO, FO-ILE users; 95% of these centers restrict SO, MCT, OO, FO-ILE to doses ≤2 g/kg/day. Twenty-two percent of centers started FO-ILE at direct bilirubin of >5 mg/dl.
CONCLUSION
The results of this survey reveal significant variability in ILE usage across the US. Lipid minimization with SO, MCT, OO, FO-ILE and initiation of FO-ILE for cholestasis at higher bilirubin thresholds are prevalent. Such reports are crucial for a better understanding of ILE use in the NICU and in future ILE development.
Substances chimiques
Fat Emulsions, Intravenous
0
Soybean Oil
8001-22-7
Fish Oils
0
Olive Oil
0
Bilirubin
RFM9X3LJ49
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-58Informations de copyright
© 2022 American Society for Parenteral and Enteral Nutrition.
Références
Calkins KL, Robinson DT. Intravenous lipid emulsions in the NICU. Neoreviews. 2020;21(2):e109-e119.
Fell GL, Nandivada P, Gura KM, Puder M. Intravenous lipid emulsions in parenteral nutrition. Adv Nutr. 2015;6(5):600-610.
Hasumi K, Naganuma S, Sato Y, Endo A. Unstable amplification of the chromosomal gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase in compactin-resistant CR200 cells. Biochim Biophys Acta. 1991;1083(3):289-297.
Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol. 2007;27(5):284-290.
Martin CR, Dasilva DA, Cluette-Brown JE, et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr. 2011;159(5):743-749.e1-2.
Vayalthrikkovil S, Bashir RA, Rabi Y, et al. Parenteral fish-oil lipid emulsions in the prevention of severe retinopathy of prematurity: a systematic review and meta-analysis. Am J Perinatol. 2017;34(7):705-715.
Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr. 2013;162(4):793-798.e791.
Gura KM, Calkins KL, Premkumar MH, Puder M. Use of intravenous soybean and fish oil emulsions in pediatric intestinal failure associated liver disease: a multicenter integrated analysis report on extrahepatic adverse events. J Pediatr. 2021;241:173-180.e1.
Dudrick SJ. History of parenteral nutrition. J Am Coll Nutr. 2009;28(3):243-251.
Raman M, Almutairdi A, Mulesa L, Alberda C, Beattie C, Gramlich L. Parenteral nutrition and lipids. Nutrients. 2017;9(4):388.
Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
US Food and Drug Administration. SMOFLIPID (lipid injectable emulsion). January 12, 2018. Accessed November 14, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207648Orig1s000TOC.cfm
US Food and Drug Administration. Drug approval package: Omegaven (fish oil triglycerides). August 24, 2018. Accessed November 14, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210589Orig1s000TOC.cfm
US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. May 3, 2022. Accessed May 26, 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process%26ApplNo=018449
Murthy K, Dykes FD, Padula MA, et al. The Children's Hospitals neonatal database: an overview of patient complexity, outcomes and variation in care. J Perinatol. 2014;34(8):582-586.
Ahmad KA, Darcy-Mahoney A, Kelleher AS, Ellsbury DL, Tolia VN, Clark RH. Longitudinal survey of COVID-19 burden and related policies in U.S. neonatal intensive care units. Am J Perinatol. 2021;38(1):93-98.
Diamond IR, Grant RC, Pencharz PB, et al. Preventing the progression of intestinal failure-associated liver disease in infants using a composite lipid emulsion: a pilot randomized controlled trial of SMOFlipid. JPEN J Parenter Enteral Nutr. 2017;41(5):866-877.
Kapoor V, Malviya MN, Soll R. Lipid emulsions for parenterally fed term and late preterm infants. Cochrane Database Syst Rev. 2019;6(6):CD013171.
Kapoor V, Malviya MN, Soll R. Lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev. 2019;6(6):CD013163.
Hill NS, Cormack BE, Little BS, Bloomfield FH. Growth and clinical outcome in very low-birth-weight infants after the introduction of a multicomponent intravenous lipid emulsion. JPEN J Parenter Enteral Nutr. 2020;44(7):1318-1327.
Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr. 2012;36(1 Suppl):81s-94s.
Torgalkar R, Dave S, Shah J, et al. Multi-component lipid emulsion vs soy-based lipid emulsion for very low birth weight preterm neonates: a pre-post comparative study. J Perinatol. 2019;39(8):1118-1124.
Uberos J, Jiménez-Montilla S, Molina-Oya M, Nieto-Gómez P, Millan IC. Morbidity outcomes of very low birth weight neonates receiving parenteral nutrition with fish oil enriched lipid emulsion or lipid emulsion with soybean oil: an observational study. Am J Perinatol. 2021;38(9):952-959.
Choudhary N, Tan K, Malhotra A. Inpatient outcomes of preterm infants receiving ω-3 enriched lipid emulsion (SMOFlipid): an observational study. Eur J Pediatr. 2018;177(5):723-731.
Repa A, Binder C, Thanhaeuser M, et al. A mixed lipid emulsion for prevention of parenteral nutrition associated cholestasis in extremely low birth weight infants: a randomized clinical trial. J Pediatr. 2018;194:87-93.e81.
Ariyawangso U, Puttilerpong C, Ratanachu-ek S, Anuntkosol M. Short-term safety and efficacy of fish-oil emulsions on the prevention of parenteral nutrition-associated liver disease in surgical neonates: a randomized controlled trial. Thai J Pharmac Sci. 2014;38(4):156-209.
Belza C, Wales JC, Courtney-Martin G, de Silva N, Avitzur Y, Wales PW. An observational study of smoflipid vs intralipid on the evolution of intestinal failure-associated liver disease in infants with intestinal failure. JPEN J Parenter Enteral Nutr. 2020;44(4):688-696.
Casson C, Nguyen V, Nayak P, et al. A comparison of Smoflipid® and Intralipid® in the early management of infants with intestinal failure. J Pediatr Surg. 2020;55(1):153-157.
Stramara L, Hernandez L, Bloom BT, Durham C. Development of parenteral nutrition-associated liver disease and other adverse effects in neonates receiving SMOFlipid or intralipid. JPEN J Parenter Enteral Nutr. 2020;44(8):1530-1534.
Löfqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):271-277.
Thanhaeuser M, Fuiko R, Oberleitner-Leeb C, et al. A randomized trial of parenteral nutrition using a mixed lipid emulsion containing fish oil in infants of extremely low birth weight: neurodevelopmental outcome at 12 and 24 months corrected age, a secondary outcome analysis. J Pediatr. 2020;226:142-148.e5.
Torgalkar R, Shah J, Dave S, et al. Fish oil-containing multicomponent lipid emulsion vs soy-based lipid emulsion and neurodevelopmental outcomes of children born < 29 weeks' gestation. J Perinatol. 2020;40(11):1712-1718.
Lam HS, Tam YH, Poon TC, et al. A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis. Neonatology. 2014;105(4):290-296.
Gura K, Premkumar MH, Calkins KL, Puder M. Intravenous fish oil monotherapy as a source of calories and fatty acids promotes age-appropriate growth in pediatric patients with intestinal failure-associated liver disease. J Pediatr. 2020;219:98-105.e4.
Modi BP, Galloway DP, Gura K, et al. ASPEN definitions in pediatric intestinal failure. JPEN J Parenter Enteral Nutr. 2021;46(1):42-59.
Javid PJ, Oron AP, Duggan CP, Squires RH, Horslen SP. The extent of intestinal failure-associated liver disease in patients referred for intestinal rehabilitation is associated with increased mortality: an analysis of the Pediatric Intestinal Failure Consortium database. J Pediatr Surg. 2018;53(7):1399-1402.
Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242(3):403-409.
Cober MP, Killu G, Brattain A, Welch KB, Kunisaki SM, Teitelbaum DH. Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr. 2012;160(3):421-427.
Ernst KD. Essential fatty acid deficiency during parenteral soybean oil lipid minimization. J Perinatol. 2017;37(6):695-697.
Lam G, Strogach IG, Baron N, Thompson JF. Normal growth and essential fatty acid status in children with intestinal failure on lipid limitation. J Pediatr Gastroenterol Nutr. 2016;62(2):335-340.
Carey AN, Rudie C, Mitchell PD, Raphael BP, Gura KM, Puder M. Essential fatty acid status in surgical infants receiving parenteral nutrition with a composite lipid emulsion: a case series. JPEN J Parenter Enteral Nutr. 2019;43(2):305-310.
Memon N, Hussein K, Hegyi T, Herdt A, Griffin IJ. Essential fatty acid deficiency with SMOFlipid reduction in an infant with intestinal failure-associated liver disease. JPEN J Parenter Enteral Nutr. 2018;43(3):438-441.
Huff KA, Breckler F, Cruse W, Szeszycki E, Vanderpool C. Pediatric SMOFlipid therapy: patient response and safety concerns. JPEN J Parenter Enteral Nutr. 2021;45(4):792-799.
de Meijer VE, Le HD, Meisel JA, Gura KM, Puder M. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
Nandivada P, Fell GL, Mitchell PD, et al. Long-term fish oil lipid emulsion use in children with intestinal failure-associated liver disease [formula: see text]. JPEN J Parenter Enteral Nutr. 2017;41(6):930-937.
Koletzko B. Human milk lipids. Ann Nutr Metab. 2016;69(suppl 2):28-40.